# US 2020/0347068 A1 · Small molecule myristate inhibitors of bcr-abl and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347068 A1
- Document ID: US20200347068A1
- Status: Published application
- Kind: A1
- Application number: 16/933,095
- Filed: 2020-07-20
- Published: 2020-11-05
- Earliest claimed: 2007-11-28
- Assignees: Dana-Farber Cancer Institute, Inc.; The Scripps Research Institute
- Applicants: Dana-Farber Cancer Institute, Inc.; The Scripps Research Institute
- Inventors: Nathanael S. GRAY; Jianming ZHANG; Barun OKRAM; Xianming DENG; Jae Won CHANG; Amy WOJCIECHOWSKI
- Web page: https://patentgrep.com/patent/US20200347068A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 239/94: Nitrogen atoms
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D 473/34: attached in position 6, e.g. adenine
- C07D 495/04: Ortho-condensed systems
- C07H 19/16: Purine radicals
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides novel heteroaryl compounds of formula (IV). Such compounds are useful for the treatment of cancers.

## Claims

### Claim 1

A compound of formula IV, or a pharmaceutically acceptable salt thereof,
wherein
each R1 is independently selected from H, an optionally substituted C1-6alkyl, an optionally substituted C3-12cycloalkyl, an optionally substituted C3-12heterocycloalkyl, an optionally substituted C6-12aryl, an optionally substituted C3-12heteroaryl, an optionally substituted C1-6aralkyl, an optionally substituted C3-6heteroaralkyl, an optionally substituted C1-6haloalkyl, an optionally substituted (CH2)nC3-12heterocycloalkyl, an optionally substituted (CH2)nC6-12aryl, an optionally substituted (CH2)nC3-12heteroaryl, an optionally substituted (CH2)nC3-12cycloalkyl, (CH2)nC(O)Rx, (CH2)nC(O)OR, (CH2)nC(O)NRxRx, —C(O)Rx, —C(S)Rx, —C(NR)Rx, halo, C1-6haloalkyl, —S(O)Rx, —S(O)2Rx, or absent;
Rx, for each occurrence, is independently, H, an optionally substituted C1-6alkyl, an optionally substituted C3-12cycloalkyl, an optionally substituted C3-12heterocycloalkyl, an optionally substituted C3-12aryl, an optionally substituted C3-12heteroaryl, or C1-6haloalkyl; and
each n is independently 0, 1 or 2.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from:

### Claim 3

A compound, or a pharmaceutically acceptable salt thereof, selected from:

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of claim 1.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, further comprising an additional therapeutic agent.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the additional therapeutic agent is an ATP-site inhibitor.

### Claim 7 (depends on 3)

A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of claim 3.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, further comprising an additional therapeutic agent.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the additional therapeutic agent is an ATP-site inhibitor.

### Claim 10 (depends on 1)

A method of treating leukemia, multiple myeloma or lymphoma in a subject, comprising administering to said subject in need thereof, an effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 1.

### Claim 11 (depends on 10)

The method of claim 10, wherein the leukemia is Chronic Myelogenous Leukemia.

### Claim 12 (depends on 10)

The method of claim 10, wherein the subject is identified as being in need of kinase inhibition, and the compound is administered to the identified subject.

### Claim 13 (depends on 10)

The method of claim 10, further comprising the step of identifying a subject in need of such treatment for a kinase activity related disorder and administering the compound to the identified subject.

### Claim 14 (depends on 10)

The method of claim 10, wherein the subject is suffering from a cell proliferative disorder or disease.

### Claim 15 (depends on 3)

A method of treating leukemia, multiple myeloma or lymphoma in a subject, comprising administering to said subject in need thereof, an effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 3.

### Claim 16 (depends on 15)

The method of claim 15, wherein the leukemia is Chronic Myelogenous Leukemia.

### Claim 17 (depends on 15)

The method of claim 15, wherein the subject is identified as being in need of kinase inhibition, and the compound is administered to the identified subject.

### Claim 18 (depends on 15)

The method of claim 15, further comprising the step of identifying a subject in need of such treatment for a kinase activity related disorder and administering the compound to the identified subject.

### Claim 19 (depends on 15)

The method of claim 15, wherein the subject is suffering from a cell proliferative disorder or disease.
